Abstract 5675: Discovery and development of an asymmetric IgG-like bispecific antibody targeting EGFR and c-MET, engineered through H-H and H-L chain charge-based heterodimerization

癌症研究 受体酪氨酸激酶 癌症 抗体 酪氨酸激酶 表皮生长因子受体 抗体依赖性细胞介导的细胞毒性 下调和上调 信号转导 化学 分子生物学 生物 免疫学 细胞生物学 单克隆抗体 生物化学 遗传学 基因
作者
Ping Wang,Weifeng Huang,Zhenting Zhao,Xiaoniu Miao,Shaogang Peng,Chao Wang,Yan Yao,Tiantian Dong,Andy Tsun,Yingda Xu,Xiaolin Liu,Luo Yi
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 5675-5675
标识
DOI:10.1158/1538-7445.am2023-5675
摘要

Abstract Background: Lung cancer remains the leading cause of cancer mortality and is the most commonly diagnosed cancer with an estimated 2.2 million cases per year. EGFR, a tyrosine kinase receptor, plays a central role in cellular proliferation, survival, differentiation, and migration. Gain-of-function somatic mutations of EGFR significantly drives disease progression. Small molecule tyrosine kinase inhibitors (TKIs), designed to inhibit EGFR signaling specific to these mutations (e.g., L858R and E19del etc.), have achieved excellent clinical outcomes. However, patients carrying TKI-insensitive mutations (e.g., E20ins) and/or those with disease progression after TKI treatment, by the upregulation of complementary signaling pathways (HGF/c-MET, etc.), remain an unmet medical need. Here, we report the discovery of a fully-human afucosylated anti-EGFR x cMET IgG-like bispecific antibody (PM1080). Methods: PM1080 was generated by introducing unique mutations to the CH1-CL domains of each binding arm to promote correct HC-LC pairing. KIH mutations were also introduced to each CH3 domain to support HC-HC heterodimerization and generate an IgG-like bispecific with one arm binding to EGFR and the other to cMET. PM1080 was expressed via a four-chain expression system in CHO cells carrying a fut8−/− knockout to generate afucosylated molecules with enhanced ADCC activity. Results: Through monovalent affinity measurements, PM1080 interacted with EGFR at single digit nanomolar affinity and at sub-nanomolar affinity to c-MET. PM1080 preferentially bound to EGFR/c-MET double-positive cells rather than EGFR single-positive cells. PM1080 blocked both EGF/EGFR and HGF/c-MET signals via physical blockade of the interaction between EGF/HGF to their corresponding receptors and induced EGFR/c-MET internalization and degradation from the cell surface. Through intricate engineering, PM1080 was expressed via a four-chain system and produced as an afucosylated antibody with significantly improved ADCC function. PM1080 induced potent anti-tumor efficacy against EGFR/c-MET-positive tumor cells as a single agent. Importantly, PM1080 induced anti-tumor activity regardless of EGFR mutations at the intracellular signaling domain, and thus may serve as a promising combinational agent to TKI therapies. As expected, synergistic anti-tumor activity was observed when PM1080 was combined with either 1st or 3rd generation TKIs in both in vitro and in vivo models. Conclusion: PM1080, a bispecific antibody targeting EGFR & c-MET was discovered for cancer treatment. PM1080 displayed potent anti-tumor efficacy either as a single agent or in combination with EGFR TKIs. Preclinical PK and toxicity studies have been conducted to support future first-in-human studies. Citation Format: Ping Wang, Weifeng Huang, Zhenting Zhao, Xiaoniu Miao, Shaogang Peng, Chao Wang, Yao Yan, Tiantian Dong, Andy Tsun, Yingda Xu, Xiaolin Liu, Luo Yi. Discovery and development of an asymmetric IgG-like bispecific antibody targeting EGFR and c-MET, engineered through H-H and H-L chain charge-based heterodimerization. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5675.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
派大星完成签到,获得积分10
刚刚
1秒前
1秒前
瘦瘦寻菡完成签到,获得积分20
1秒前
Nole的应助被Jingxue_ZX采纳,获得30
2秒前
lbh发布了新的文献求助10
2秒前
放青松完成签到,获得积分10
4秒前
Hello的应助被细腻飞鸟采纳,获得10
4秒前
4秒前
晚风轻吹完成签到,获得积分10
4秒前
可爱的函函的应助被火山采纳,获得10
5秒前
精明之瑶完成签到,获得积分20
6秒前
可燃冰完成签到,获得积分10
6秒前
无限孤云完成签到,获得积分10
6秒前
yijiahu完成签到 ,获得积分10
7秒前
7秒前
7秒前
甜甜的觅夏完成签到,获得积分10
7秒前
7秒前
懵懂的蜜蜂完成签到 ,获得积分10
8秒前
沉默是金完成签到,获得积分10
8秒前
8秒前
8秒前
爱学习的何旭完成签到,获得积分10
9秒前
希望天下0贩的0的应助被Jessica采纳,获得10
9秒前
9秒前
9秒前
哈哈哈完成签到,获得积分10
11秒前
好运完成签到 ,获得积分10
11秒前
海阔天空发布了新的文献求助10
12秒前
12秒前
完美世界的应助被xiaowu采纳,获得10
12秒前
13秒前
13秒前
yijiahu关注了科研通微信公众号
14秒前
14秒前
14秒前
孙浩文发布了新的文献求助10
14秒前
无花果的应助被善良语雪采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698